Effectiveness of SARS-CoV-2 MRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States

Background: As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand the real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes.

Methods: In a multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, we evaluated vaccine effectiveness to prevent Covid-19 hospitalizations by comparing odds of prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with Covid-19 and hospital-based controls who tested negative for SARS-CoV-2.

Results: Among 1210 participants, median age was 58 years, 22.8% were Black, 13.8% were Hispanic, and 20.6% had immunosuppression. SARS-CoV-2 lineage B.1.1.7 was most common variant (59.7% of sequenced viruses). Full vaccination (receipt of two vaccine doses ≥14 days before illness onset) had been received by 45/590 (7.6%) cases and 215/620 (34.7%) controls. Overall vaccine effectiveness was 86.9% (95% CI: 80.4 to 91.2%). Vaccine effectiveness was similar for Pfizer-BioNTech and Moderna vaccines, and highest in adults aged 18-49 years (97.3%; 95% CI: 78.9 to 99.7%). Among 45 patients with vaccine-breakthrough Covid hospitalizations, 44 (97.8%) were ≥50 years old and 20 (44.4%) had immunosuppression. Vaccine effectiveness was lower among patients with immunosuppression (59.2%; 95% CI: 11.9 to 81.1%) than without immunosuppression (91.3%; 95% CI: 85.5 to 94.7%).

Conclusion: During March-May 2021, SARS-CoV-2 mRNA vaccines were highly effective for preventing Covid-19 hospitalizations among US adults. SARS-CoV-2 vaccination was beneficial for patients with immunosuppression, but effectiveness was lower in the immunosuppressed population.

Citing Articles

COVID-19 Vaccination Coverage and Factors Associated With Vaccine Uptake Among People With HIV.

Hechter R, Qian L, Liu I, Sy L, Ryan D, Xu S JAMA Netw Open. 2024; 7(6):e2415220.

PMID: 38842808 PMC: 11157350. DOI: 10.1001/jamanetworkopen.2024.15220.

Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site.

van Vliet V, Huynh N, Pala J, Patel A, Singer A, Slater C PLoS Pathog. 2022; 18(12):e1011065.

PMID: 36548304 PMC: 9822107. DOI: 10.1371/journal.ppat.1011065.

Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies.

Wallace M, Collins J, Moline H, Plumb I, Godfrey M, Morgan R PLoS One. 2022; 17(12):e0278624.

PMID: 36473010 PMC: 9725157. DOI: 10.1371/journal.pone.0278624.

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.

Kumari M, Lu R, Li M, Huang J, Hsu F, Ko S J Biomed Sci. 2022; 29(1):68.

PMID: 36096815 PMC: 9465653. DOI: 10.1186/s12929-022-00852-9.

COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.

Havers F, Pham H, Taylor C, Whitaker M, Patel K, Anglin O JAMA Intern Med. 2022; 182(10):1071-1081.

PMID: 36074486 PMC: 9459904. DOI: 10.1001/jamainternmed.2022.4299.

References

Ferdinands J, Gaglani M, Martin E, Middleton D, Monto A, Murthy K . Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2018; 220(8):1265-1275. PMC: 6743848. DOI: 10.1093/infdis/jiy723. View

Patel M, Chen J, Kim S, Garg S, Flannery B, Haddadin Z . Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States. Emerg Infect Dis. 2020; 26(8):1720-1730. PMC: 7392442. DOI: 10.3201/eid2608.191493. View

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

Foppa I, Haber M, Ferdinands J, Shay D . The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine. 2013; 31(30):3104-9. DOI: 10.1016/j.vaccine.2013.04.026. View

Hollis N, Li W, Van Dyke M, Njie G, Scobie H, Parker E . Racial and Ethnic Disparities in Incidence of SARS-CoV-2 Infection, 22 US States and DC, January 1-October 1, 2020. Emerg Infect Dis. 2021; 27(5):1477-1481. PMC: 8084494. DOI: 10.3201/eid2705.204523. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Lauer S, Grantz K, Bi Q, Jones F, Zheng Q, Meredith H . The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020; 172(9):577-582. PMC: 7081172. DOI: 10.7326/M20-0504. View

Jackson M, Chung J, Jackson L, Phillips C, Benoit J, Monto A . Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. N Engl J Med. 2017; 377(6):534-543. PMC: 5727917. DOI: 10.1056/NEJMoa1700153. View

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

10.

Tenforde M, Olson S, Self W, Talbot H, Lindsell C, Steingrub J . Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(18):674-679. PMC: 9368749. DOI: 10.15585/mmwr.mm7018e1. View

11.

Roth G, Emmons-Bell S, Alger H, Bradley S, Das S, de Lemos J . Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic. JAMA Netw Open. 2021; 4(5):e218828. PMC: 8094014. DOI: 10.1001/jamanetworkopen.2021.8828. View

12.

Garg S, Kim L, Whitaker M, OHalloran A, Cummings C, Holstein R . Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(15):458-464. PMC: 7755063. DOI: 10.15585/mmwr.mm6915e3. View

13.

Thompson M, Burgess J, Naleway A, Tyner H, Yoon S, Meece J . Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December.... MMWR Morb Mortal Wkly Rep. 2021; 70(13):495-500. PMC: 8022879. DOI: 10.15585/mmwr.mm7013e3. View

14.

Durand C . Does raising type 1 error rate improve power to detect interactions in linear regression models? A simulation study. PLoS One. 2013; 8(8):e71079. PMC: 3745431. DOI: 10.1371/journal.pone.0071079. View

15.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

16.

Ruddy J, Connolly C, Boyarsky B, Werbel W, Christopher-Stine L, Garonzik-Wang J . High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021; 80(10):1351-1352. PMC: 8843949. DOI: 10.1136/annrheumdis-2021-220656. View

17.

Lewnard J, Patel M, Jewell N, Verani J, Kobayashi M, Tenforde M . Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines. Epidemiology. 2021; 32(4):508-517. PMC: 8168935. DOI: 10.1097/EDE.0000000000001366. View

18.

Tenforde M, Talbot H, Trabue C, Gaglani M, McNeal T, Monto A . Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019-2020. J Infect Dis. 2020; 224(5):813-820. PMC: 8408767. DOI: 10.1093/infdis/jiaa800. View

19.

Feldstein L, Ferdinands J, Self W, Randolph A, Aboodi M, Baughman A . Modeling the Impacts of Clinical Influenza Testing on Influenza Vaccine Effectiveness Estimates. J Infect Dis. 2021; 224(12):2035-2042. PMC: 8967445. DOI: 10.1093/infdis/jiab273. View

20.

Grijalva C, Feldstein L, Talbot H, Aboodi M, Baughman A, Brown S . Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019-2020: A Test-Negative Study. Clin Infect Dis. 2021; 73(8):1459-1468. PMC: 8682606. DOI: 10.1093/cid/ciab462. View